Citations (68)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Sean Wharton, Lilian Raiber, Kristin J Serodio, Jasmine Lee & Rebecca AG Christensen. (2018) Medications that cause weight gain and alternatives in Canada: a narrative review. Diabetes, Metabolic Syndrome and Obesity 11, pages 427-438.
Read now
Read now
Nesrin Dilbaz. (2015) New Targets for the Management of Schizophrenia. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 25:4, pages 407-428.
Read now
Read now
Adityanjee, Ann Romine, Eric Brown, Paul Thuras, Susanne Lee & S. Charles Schulz. (2008) Quetiapine in Patients with Borderline Personality Disorder: An Open-Label Trial. Annals of Clinical Psychiatry 20:4, pages 219-226.
Read now
Read now
Michael Riedel, Norbert Müller, Martin Strassnig, Ilja Spellmann, Emanuel Severus & Hans-Jürgen Möller. (2007) Quetiapine in the treatment of schizophrenia and related disorders. Neuropsychiatric Disease and Treatment 3:2, pages 219-235.
Read now
Read now
Jonathan S. E. Hellewell. (2007) Quetiapine demonstrates good tolerability and is associated with improvements in extrapyramidal symptoms in patients with schizophrenia switched from other antipsychotics: results of a naturalistic study. International Journal of Psychiatry in Clinical Practice 11:2, pages 112-122.
Read now
Read now
Martin Lambert, Paul-Egbert Reimitz & Dieter Naber. (2006) Effectiveness, tolerability and subjective well-being in patients receiving quetiapine: findings of a post-marketing surveillance study in schizophrenia. International Journal of Psychiatry in Clinical Practice 10:3, pages 204-212.
Read now
Read now
Arshia A. Shirzadi & S. Nassir Ghaemi. (2006) Side Effects of Atypical Antipsychotics: Extrapyramidal Symptoms and the Metabolic Syndrome. Harvard Review of Psychiatry 14:3, pages 152-164.
Read now
Read now
Torsten Gruettert & Lars Friege. (2005) Quetiapine in patients with borderline personality disorder and psychosis: a case series. International Journal of Psychiatry in Clinical Practice 9:3, pages 180-186.
Read now
Read now
Kelda H Walsh & Christopher J McDougle. (2004) Pharmacological augmentation strategies for treatment-resistant obsessive-compulsive disorder. Expert Opinion on Pharmacotherapy 5:10, pages 2059-2067.
Read now
Read now
Joyce G. Small, Madeleine C. Kolar & Jeffrey J. Kellams. (2004) Quetiapine in schizophrenia: onset of action within the first week of treatment. Current Medical Research and Opinion 20:7, pages 1017-1023.
Read now
Read now
A De Nayer, E Windhager, Irmansyah, I Larmo, B Lindenbauer, H Rittmannsberger, T Platz, Am Jones, Jl Whiteford & Ca Altman. (2003) Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. International Journal of Psychiatry in Clinical Practice 7:1, pages 59-66.
Read now
Read now
Jes Gerlach. (2002) Improving Outcome in Schizophrenia: The Potential Importance of EPS and Neuroleptic Dysphoria. Annals of Clinical Psychiatry 14:1, pages 47-57.
Read now
Read now
Articles from other publishers (56)
David M. Taylor, Thomas R. E. Barnes & Allan H. Young. 2021. The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry
1
224
.
K.P. Singh & Manoj Kr. Singh. (2017) In utero exposure to atypical antipsychotic drug, risperidone: Effects on fetal neurotoxicity in hippocampal region and cognitive impairment in rat offspring. Progress in Neuro-Psychopharmacology and Biological Psychiatry 75, pages 35-44.
Crossref
Crossref
Nikhil Nihalani, Thomas L. Schwartz, Umar A. Siddiqui & James L. Megna. (2011) Obesity and Psychotropics. CNS Neuroscience & Therapeutics 18:1, pages 57-63.
Crossref
Crossref
Nikhil Nihalani, Thomas L. Schwartz, Umar A. Siddiqui & James L. Megna. (2011) Weight Gain, Obesity, and Psychotropic Prescribing. Journal of Obesity 2011, pages 1-9.
Crossref
Crossref
Glen I. Spielmans & Peter I. Parry. (2010) From Evidence-based Medicine to Marketing-based Medicine: Evidence from Internal Industry Documents. Journal of Bioethical Inquiry 7:1, pages 13-29.
Crossref
Crossref
David Taylor, Carol Paton & Shitij Kapur. 2009. The Maudsley Prescribing Guidelines, Tenth Edition. The Maudsley Prescribing Guidelines, Tenth Edition
9
122
.
S. Gentile. (2009) Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications. Obesity Reviews 10:5, pages 527-542.
Crossref
Crossref
W. Victor R. Vieweg, James R. Levy, Sonja K. Fredrickson, Stuart R. Chipkin, Mary Beatty-Brooks, Antony Fernandez, Mehrul Hasnain & Anand K. Pandurangi. (2008) Psychotropic Drug Considerations in Depressed Patients with Metabolic Disturbances. The American Journal of Medicine 121:8, pages 647-655.
Crossref
Crossref
Silvio Bellino, Erika Paradiso & Filippo Bogetto. (2008) Efficacy and Tolerability of Pharmacotherapies for Borderline Personality Disorder. CNS Drugs 22:8, pages 671-692.
Crossref
Crossref
Robert Conley & Deanna Kelly. (2007) Clinical Pharmacology and Medication-Associated Side Effects: A Review of Second-Generation Antipsychotics for Schizophrenia. Clinical Schizophrenia & Related Psychoses 1:2, pages 135-146.
Crossref
Crossref
P. Bosanac, S. Kurlender, T. Norman, K. Hallam, K. Wesnes, T. Manktelow & G. Burrows. (2007) An open-label study of quetiapine in anorexia nervosa. Human Psychopharmacology: Clinical and Experimental 22:4, pages 223-230.
Crossref
Crossref
Mazlum Copur, Baki Arpaci, Turkay Demir & Halis Narin. (2007) Clinical Effectiveness of Quetiapine in Children and Adolescents with Tourette???s Syndrome. Clinical Drug Investigation 27:2, pages 123-130.
Crossref
Crossref
Peter M Haddad & Sonu G Sharma. (2007) Adverse Effects of Atypical Antipsychotics. CNS Drugs 21:11, pages 911-936.
Crossref
Crossref
L. Douglas Ried, Bernard T. Renner, Joel R. McConkey, Michael A. Bengtson & Larry M. Lopez. (2006) Increased Cardiovascular Risk with Second-Generation Antipsychotic Agent Switches. Journal of the American Pharmacists Association 46:4, pages 491-501.
Crossref
Crossref
Pietro Gareri, Pasquale De Fazio, Salvatore De Fazio, Norma Marigliano, Guido Ferreri Ibbadu & Giovambattista De Sarro. (2006) Adverse Effects of Atypical Antipsychotics in the Elderly. Drugs & Aging 23:12, pages 937-956.
Crossref
Crossref
Salvatore Gentile. (2006) Long-Term Treatment with Atypical Antipsychotics and the Risk of Weight Gain. Drug Safety 29:4, pages 303-319.
Crossref
Crossref
Peter J. Weiden. (2005) Switching antipsychotics: an updated review with a focus on quetiapine. Journal of Psychopharmacology 20:1, pages 104-118.
Crossref
Crossref
Frank-Gerald B. PajonkAnne K. Schwertner & Marko Alexander Seelig. (2005) Rapid dose titration of quetiapine for the treatment of acute schizophrenia and acute mania: a case series. Journal of Psychopharmacology 20:1, pages 119-124.
Crossref
Crossref
Hugo A. Wolters, Rikus Knegtering, Durk Wiersma & Robert J. van den Bosch. (2006) Evaluation of the Subjects' Response to Antipsychotics Questionnaire. International Clinical Psychopharmacology 21:1, pages 63-69.
Crossref
Crossref
Ilkka Larmo, André de Nayer, Elmar Windhager, Irmansyah, Bernhard Lindenbauer, Hans Rittmannsberger, Thomas Platz, A. Martin Jones & Charles Altman. (2005) Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. Human Psychopharmacology: Clinical and Experimental 20:8, pages 573-581.
Crossref
Crossref
Peter Haddad. (2016) Weight change with atypical antipsychotics in the treatment of schizophrenia. Journal of Psychopharmacology 19:6_suppl, pages 16-27.
Crossref
Crossref
. 2005. The Maudsley 2005-2006 Prescribing Guidelines. The Maudsley 2005-2006 Prescribing Guidelines
7
106
.
P. Mackin, H. M. Watkinson & A. H. Young. (2005) Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia 48:2, pages 215-221.
Crossref
Crossref
John W. Newcomer. (2005) Second-Generation (Atypical) Antipsychotics and Metabolic Effects. CNS Drugs 19:Supplement 1, pages 1???93.
Crossref
Crossref
Deanna L Kelly, Robert R Conley & William T Carpenter. (2005) First-Episode Schizophrenia. Drugs 65:8, pages 1113-1138.
Crossref
Crossref
Joseph Peuskens. (2004) Clinical effectiveness in adults with chronic schizophrenia. European Neuropsychopharmacology 14, pages S453-S459.
Crossref
Crossref
Siegfried Kasper, Martin Brecher, Lesley Fitton & Andrew Martin Jones. (2004) Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. International Clinical Psychopharmacology 19:5, pages 281-289.
Crossref
Crossref
Sanjay Gupta, Prakash S Masand, Shubdeep Virk, Thomas Schwartz, Ahmed Hameed, Bradford L Frank & Kari Lockwood. (2004) Weight decline in patients switching from olanzapine to quetiapine. Schizophrenia Research 70:1, pages 57-62.
Crossref
Crossref
T. L. Schwartz, N. Nihalani, S. Jindal, S. Virk & N. Jones. (2004) Psychiatric medication-induced obesity: a review. Obesity Reviews 5:2, pages 115-121.
Crossref
Crossref
Peter F. Buckley. (2004) Maintenance treatment for schizophrenia with quetiapine. Human Psychopharmacology: Clinical and Experimental 19:2, pages 121-124.
Crossref
Crossref
Denise A Sprague, Peter S Loewen & Colette B Raymond. (2004) Selection of Atypical Antipsychotics for the Management of Schizophrenia. Annals of Pharmacotherapy 38:2, pages 313-319.
Crossref
Crossref
Peter F. Buckley, Jeffrey M. Goldstein & Robin A. Emsley. (2004) Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schizophrenia Research 66:2-3, pages 143-150.
Crossref
Crossref
Roopa Sathyaprakash & Robert R. Henry. (2004) Hyperglycemia with antipsychotic treatment. Current Diabetes Reports 4:1, pages 41-45.
Crossref
Crossref
Susan M Cheer & Antona J Wagstaff. (2004) Quetiapine. CNS Drugs 18:3, pages 173-199.
Crossref
Crossref
Hans-Peter Volz, Siegfried Kasper & Hans-Jürgen MöllerHans-Peter Volz. 2004. Kasuistische Beiträge zur modernen Pharmakotherapie mit Quetiapin. Kasuistische Beiträge zur modernen Pharmakotherapie mit Quetiapin
60
88
.
Roger S McIntyre, Kostas Trakas, Daryl Lin, Robert Balshaw, Pieway Hwang, Kimberly Robinson & Andrew Eggleston. (2016) Risk of Weight Gain Associated with Antipsychotic Treatment: Results from the Canadian National Outcomes Measurement Study in Schizophrenia. The Canadian Journal of Psychiatry 48:10, pages 689-694.
Crossref
Crossref
U Werneke, D Taylor, T.A.B. Sanders & S Wessely. (2003) Behavioural management of antipsychotic-induced weight gain: a review. Acta Psychiatrica Scandinavica 108:4, pages 252-259.
Crossref
Crossref
KE Bryden, DM Gardner & LC Kopala. (2003) FIRST EPISODE PSYCHOSIS: EARLY INTERVENTION STRATEGIES WITH SECOND‐GENERATION ANTIPSYCHOTIC MEDICATIONS. International Journal of Clinical Practice 57:6, pages 513-518.
Crossref
Crossref
S.Charles Schulz, Ruth Thomson & Martin Brecher. (2003) The efficacy of quetiapine vs. haloperidol and placebo: a meta-analytic study of efficacy. Schizophrenia Research 62:1-2, pages 1-12.
Crossref
Crossref
A MortimerP WilliamsD Meddis. (2003) Impact of Side-Effects of Atypical Antipsychotics on Non-Compliance, Relapse and Cost. Journal of International Medical Research 31:3, pages 188-196.
Crossref
Crossref
Norman Sussman. (2003) The Implications of Weight Changes with Antipsychotic Treatment. Journal of Clinical Psychopharmacology 23:3, pages S21-S26.
Crossref
Crossref
Rajiv Tandon. (2003) Improvement Without Impairment: A Review of Clinical Data for Quetiapine in the Treatment of Schizophrenia. Journal of Clinical Psychopharmacology 23:3, pages S15-S20.
Crossref
Crossref
Jean Addington, Chrystal Mansley & Donald Addington. (2016) Weight Gain in First-Episode Psychosis. The Canadian Journal of Psychiatry 48:4, pages 272-276.
Crossref
Crossref
&NA;. (2003) Recommendations. Current Opinion in Psychiatry 16, pages S21-S28.
Crossref
Crossref
Pietro Gareri, Pasquale De Fazio, Mariagrazia Stilo, Guido Ferreri & Giovambattista De Sarro. (2003) Conventional and Atypical Antipsychotics in the Elderly. Clinical Drug Investigation 23:5, pages 287-322.
Crossref
Crossref
Michael J. Reinstein, John G. Sonnenberg, Sangarapillai C. Mohan, Maxim A. Chasanov & Lynne E. Jones. (2003) Use of Quetiapine to Manage Patients Who Experienced Adverse Effects with Clozapine. Clinical Drug Investigation 23:1, pages 63-67.
Crossref
Crossref
H. Nasrallah. (2003) A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 28, pages 83-96.
Crossref
Crossref
R. Tandon & M.D. Jibson. (2003) Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28, pages 9-26.
Crossref
Crossref
Jonathan SE Hellewell. (2002) Quetiapine: a well-tolerated and effective atypical antipsychotic. Hospital Medicine 63:10, pages 600-603.
Crossref
Crossref
Howard C. Margolese, Guy Chouinard, Linda Beauclair & Marie-Claire Bélanger. (2002) Therapeutic Tolerance and Rebound Psychosis During Quetiapine Maintenance Monotherapy in Patients With Schizophrenia and Schizoaffective Disorder. Journal of Clinical Psychopharmacology 22:4, pages 347-352.
Crossref
Crossref
U. Werneke, D. Taylor & T.A.B. Sanders. (2002) Options for pharmacological management of obesity in patients treated with atypical antipsychotics. International Clinical Psychopharmacology 17:4, pages 145-160.
Crossref
Crossref
Andrew J. Cutler, Jeffrey M. Goldstein & John A. Tumas. (2002) Dosing and switching strategies for quetiapine fumarate. Clinical Therapeutics 24:2, pages 209-222.
Crossref
Crossref
N. Mohr, B. Vythilingum, R. A. Emsley & D. J. Stein. (2002) Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. International Clinical Psychopharmacology 17:1, pages 37-40.
Crossref
Crossref
Jamie Mullen, Michael D Jibson & Dennis Sweitzer. (2001) A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clinical Therapeutics 23:11, pages 1839-1854.
Crossref
Crossref
Siegfried Kasper, Johannes Tauscher & Angela Heiden. (2001) Quetiapine: efficacy and tolerability in schizophrenia. European Neuropsychopharmacology 11, pages S405-S413.
Crossref
Crossref
. (2001) Current Awareness. Human Psychopharmacology: Clinical and Experimental 16:4, pages 363-368.
Crossref
Crossref